TCM
DNA icon

Traynor Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Traynor Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-197
Closed -$14.3K – 253
2023
Q3 		$14.3K Buy
197
+12
+6% +$959 ﹤0.01% 218
2023
Q2 		$13.8K Buy
+185
New +$11K ﹤0.01% 213

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Traynor Capital Management's DNA Position: Q4 2023 in Review

Traynor Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 197 shares — an estimated $14.3K sold.

Traynor Capital Management first reported a position in DNA in Q2 2023 and held it in 2 quarters. The position peaked at $14.3K in Q3 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.

  • Traynor Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
  • Traynor Capital Management sold 197 Ginkgo Bioworks shares in Q4 2023, an estimated $14.3K.
  • Traynor Capital Management first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 2 quarters.
  • Traynor Capital Management's Ginkgo Bioworks position peaked at $14.3K in Q3 2023.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.

Based on Traynor Capital Management's 13F filing for Q4 2023, filed 18 Jan 2024.